NEW YORK, Aug. 29 – Pyrosequencing and the University of Geneva have partnered to develop a diagnostic test for Down Syndrome, the company announced on Wednesday.

The molecular diagnostics business unit of Pyrosequencing will sponsor the university's research to analyze genes and develop a test based on the company's technology. Pyrosequencing said it had secured exclusive access to the intellectual property underlying the University of Geneva’s method to detect the gene.

Financial details of the agreement were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.